Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827304 | 0.86 | CYP1A2 (0.41) | CYP1A2FDPS | |
| SCHEMBL12044431 | 0.84 | CYP1A2 (0.40) | CYP1A2FDPS | |
| SCHEMBL27832728 | 0.82 | CES2 (0.42) | CYP1A2FDPS | |
| SCHEMBL18597036 | 0.81 | TDP1 (0.33) | CYP1A2TDP1ELANEMEN1KMT2A | |
| SCHEMBL13911892 | 0.80 | CYP1A2 (0.43) | CYP1A2 | |
| SCHEMBL18597122 | 0.79 | ELANE (0.36) | TDP1ELANEMEN1KMT2ALMNA | |
| SCHEMBL10044964 | 0.79 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL6831794 | 0.78 | CYP1A2 (0.42) | CYP1A2MEN1KMT2ACYP3A4 | |
| SCHEMBL17192924 | 0.78 | FDPS (0.34) | CYP1A2TDP1LMNAALDH1A1HSD17B10 | |
| SCHEMBL25575218 | 0.78 | SLC7A5 (0.39) | TDP1ELANEMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2017-07-13 | — | — | US | disclosed |
| US-9585965-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-07 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | ALKERMES PHARMA IRELAND LTD (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-9072788-B2 | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-07 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | ALKERMES, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2008084046-A1 | PLASTICIZERS FOR POLYVINYL ACETALS AND POLYSULFIDES | BASF SE (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CYP1A2 3477/4885TDP1 3315/4885ELANE 3195/4885 |
| US-20150320875-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | CYP1A2 1838/4885TDP1 3502/4885ELANE 419/4885 |
| US-20170196848-A1 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives | PHPT1, SI, CA6 | CYP1A2 1838/4885TDP1 3502/4885ELANE 419/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP1A2 3477/4885TDP1 3315/4885ELANE 3195/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CYP1A2 3477/4885TDP1 3315/4885ELANE 3195/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | CYP1A2 3477/4885TDP1 3315/4885ELANE 3195/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP1A2 4012/4885TDP1 3152/4885ELANE 2705/4885 |
| US-20110319422-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES | PHPT1, SI, CA6 | CYP1A2 1838/4885TDP1 3502/4885ELANE 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.